Alembic Pharmaceuticals reported robust Q3 results, posting an 11% revenue increase to ₹1,876.3 crore. The company maintained steady EBITDA margins at 15.6%. Net profit saw a dip due to a one-time provision related to new labor codes. Growth was driven by consistent execution in the India and US markets, which each recorded 6% year-on-year expansion. The company also advanced its R&D pipeline and received multiple ANDA approvals.
Operational Strength Amidst Profit Dip
The net profit decline of 4.1% to ₹132 crore was primarily attributed to a ₹42 crore one-time provision set aside for employee benefits, a consequence of adjustments mandated by India's new labor code. Despite this accounting impact, the underlying operational strength remained evident, with total revenue climbing 10.8% year-on-year to ₹1,876.3 crore.
India and International Markets Show Resilience
The India branded business demonstrated resilience, achieving 6% year-on-year growth to ₹652 crore. This expansion was fueled by strong performances in the gynaecology, ophthalmology, and animal healthcare segments, alongside the introduction of four new products and alignment with market trends in its anti-infective portfolio. Similarly, the United States generics market contributed a 6% uplift to revenue, reaching ₹553 crore, bolstered by two new product launches during the fiscal third quarter.
Ex-US Momentum and API Business
International generics outside the US displayed exceptional momentum, surging 36% year-on-year to ₹406 crore. The Active Pharmaceutical Ingredient (API) business saw a more modest 2% increase, contributing ₹264 crore to the topline.
R&D Investment and Pipeline Expansion
Alembic Pharmaceuticals maintained a strategic focus on research and development, investing approximately 9% of its revenue back into innovation. The company also progressed with the integration of Utility Therapeutics, with the launch of Pivya™ slated for the fourth quarter. This move is expected to significantly bolster its branded portfolio in the United States.
Approvals and Market Reaction
During the quarter, the company secured seven Abbreviated New Drug Application (ANDA) approvals, expanding its cumulative approvals to 232. Following the earnings release, shares of Alembic Pharmaceuticals Ltd. saw a positive reaction, trading 1.79% higher at ₹812.65 on the National Stock Exchange (NSE).
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.
